This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://localhost/temp/predkladatel/
n11http://linked.opendata.cz/resource/domain/vavai/projekt/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/ontology/domain/vavai/
n4http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n6http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F14%3A33144644%21RIV15-MSM-15110___/
n20http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n15http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F14%3A33144644%21RIV15-MSM-15110___
rdf:type
skos:Concept n18:Vysledek
dcterms:description
Aims: A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment. Methods: A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and { 90%). Reduced RDI in two groups (90-99% and { 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared. Results: Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13). Conclusion: We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients. Aims: A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment. Methods: A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and { 90%). Reduced RDI in two groups (90-99% and { 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared. Results: Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13). Conclusion: We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients.
dcterms:title
Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma
skos:prefLabel
Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma
skos:notation
RIV/61989592:15110/14:33144644!RIV15-MSM-15110___
n3:aktivita
n16:S n16:P n16:Z
n3:aktivity
P(EE2.3.20.0170), S, Z(MSM6198959205)
n3:cisloPeriodika
3
n3:dodaniDat
n15:2015
n3:domaciTvurceVysledku
n5:3461904 n5:2556049 n5:1672665 n5:8731764 n5:1943545 n5:3591263
n3:druhVysledku
n17:J
n3:duvernostUdaju
n19:S
n3:entitaPredkladatele
n6:predkladatel
n3:idSjednocenehoVysledku
41701
n3:idVysledku
RIV/61989592:15110/14:33144644
n3:jazykVysledku
n9:eng
n3:klicovaSlova
therapeutic outcome; relative dose intensity; chemotherapy; primary treatment; Hodgkin lymphoma
n3:klicoveSlovo
n12:therapeutic%20outcome n12:relative%20dose%20intensity n12:Hodgkin%20lymphoma n12:chemotherapy n12:primary%20treatment
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[65B608A3F1C6]
n3:nazevZdroje
Biomedical Papers-Olomouc
n3:obor
n14:FD
n3:pocetDomacichTvurcuVysledku
6
n3:pocetTvurcuVysledku
8
n3:projekt
n11:EE2.3.20.0170
n3:rokUplatneniVysledku
n15:2014
n3:svazekPeriodika
158
n3:tvurceVysledku
Mlčůchová, Dana Procházka, Vít Indrák, Karel Faber, Edgar Raida, Luděk Rusiňáková, Zuzana Tuček, Pavel Papajík, Tomáš
n3:zamer
n4:MSM6198959205
s:issn
1213-8118
s:numberOfPages
5
n20:doi
10.5507/bp.2013.022
n10:organizacniJednotka
15110